Preclinical Research – Page 4

Species selection questioned during regulatory submission prep – FDA/EMA non-clinical expectations

Identifying symptoms early can significantly improve the response to species selection challenges. Symptoms may manifest in several ways, including:Click to read the full article.

Species selection questioned during IND-enabling studies – FDA/EMA non-clinical expectations

Investigating Species Selection Concerns in IND-Enabling Studies for Regulatory Compliance In the intricate landscape of drug development, the species selection in IND-enabling studies has become a focal point for scrutiny.…

Dose justification weak during regulatory submission prep – FDA/EMA non-clinical expectations

Identifying weak dose justification starts with recognizing specific symptoms or signals that suggest potential deficiencies in preclinical studies. Some common indicators include:Click to read the full article.

Study design not regulator-aligned during study audit – FDA/EMA non-clinical expectations

Identifying symptoms of misalignment begins with observing signals on the laboratory floor or during study audits. Common signals include:Click to read the full article.

GLP readiness concerns during study audit – how to defend preclinical package

An effective investigation begins with recognizing the symptoms of GLP readiness concerns. During a study audit, several symptoms may surface, signaling potential compliance issues:Click to read the full article.

Reproducibility gaps during study audit – preventing clinical hold

The initial identification of reproducibility gaps often arises from a range of subtle and overt signals during study audits or routine laboratory evaluations. These symptoms may include:Click to read the…

Dose justification weak during regulatory submission prep – regulatory deficiency risk analysis

Weak Dose Justifications During Regulatory Submission Prep: An Investigative Approach The preparation of regulatory submissions, particularly those concerning dose justification, is a critical phase in the drug development process. A…

Dose justification weak during program hold risk review – CAPA for study design gaps

Symptoms indicating weak dose justification in program hold risk reviews can emerge from various sources within the organization. These may include:Click to read the full article.

Species selection questioned during sponsor oversight – CAPA for study design gaps

Identifying early signs of issues with species selection is essential for timely interventions. Symptoms may arise in several forms:Click to read the full article.

Non-clinical toxicity findings during sponsor oversight – CAPA for study design gaps

Identifying early symptoms of non-clinical toxicity is crucial for timely intervention. Key signals may include:Click to read the full article.

Species selection questioned during regulatory submission prep – regulatory deficiency risk analysis

When species selection is questioned during the regulatory submission process, several symptoms or signals may emerge that indicate potential deficiencies in preclinical study design:Click to read the full article.

Dose justification weak during program hold risk review – how to defend preclinical package

Identifying symptoms or signals that indicate a weak dose justification during a program hold risk review is the first step in the investigative process. Such signals may arise from various…